At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about how immunotherapy has influenced treatment for patients with bladder cancer.
CancerNetwork® spoke with Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology and co-leader of Cancer Signaling Networks at Yale Cancer Center, about using maintenance immunotherapy as a standard of care for patients with bladder cancer. He spoke on the topic at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®), for which he served as meeting co-chair.
Immunotherapy is now considered standard of care for patients who respond to frontline chemotherapy for metastatic urothelial carcinoma. By respond, I define that as stable, complete, or partial response to chemotherapy, which could be either cisplatin and gemcitabine, carboplatin and gemcitabine, or the MVAC regimen [which includes methotrexate, vinblastine sulfate, doxorubicin hydrochloride, and cisplatin]. There’s a significant improvement in survival in those patients who receive maintenance of avelumab [Bavencio] compared with those who receive just best standard of care in that setting. We view that as standard treatment for these patients.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.